Edition:
India

Fate Therapeutics Inc (FATE.OQ)

FATE.OQ on NASDAQ Stock Exchange Global Market

14.53USD
21 Oct 2019
Change (% chg)

-- (--)
Prev Close
$14.53
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
271,203
52-wk High
$22.82
52-wk Low
$11.00

Revenue & Earnings Per Share

    Revenue* Earnings Per Share**
FY 2019 Mar '19 2.63 -0.304
FY 2018 Dec '18 1.66 -0.248
Sep '18 1.03 -0.310
Jun '18 1.03 -0.370
Mar '18 1.03 -0.268
FY 2017 Dec '17 1.03 -0.286
Sep '17 1.03 -0.258
Jun '17 1.03 -0.233
Mar '17 1.03 -0.245
 
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars

Consensus Estimates Analysis

  # of Estimates Mean High Low 1 Year Ago
SALES (in millions)
Quarter Ending Dec-19 10 1.11 1.75 0.00 0.50
Quarter Ending Mar-20 6 1.05 1.60 0.29 --
Year Ending Dec-19 11 6.02 8.10 2.63 2.29
Year Ending Dec-20 10 6.64 20.31 1.14 28.51
Earnings (per share)
Quarter Ending Dec-19 12 -0.35 -0.19 -0.40 -0.30
Quarter Ending Mar-20 7 -0.34 -0.15 -0.42 --
Year Ending Dec-19 12 -1.33 -0.86 -1.47 -1.18
Year Ending Dec-20 12 -1.35 -0.47 -1.68 -1.03
Sales and Profit Figures in US Dollar (USD);

Valuation Ratios

Dividends

Growth Rates

Financial Strength

Profitability Ratios

Efficiency

Management Effectiveness

  1 Year 3 Year 5 Year
Sales % 15.44 24.93 37.31
EPS (TTM) % -15.84 -- --
Dividend % -- -- --
Note: Units in Millions of US Dollars

Performance for Fate Therapeutics Inc

Period %
Actual
% vs.
S&P 500
Rank In
Industry
Industry
Rank
4 Week 10.84 7.76 84 --
13 Week 29.76 26.07 87 --
26 Week 55.28 36.75 87 --
52 Week 142.98 127.85 95 --
YTD 75.37 45.29 85 --
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.

Institutional Holders

% Shares Owned: 98.81%
# of Holders: 174
Total Shares Held: 64,410,388
3 Mo. Net Change: 632,007
# New Positions: 7
# Closed Positions: 0
# Increased Positions: 13
# Reduced Positions: 8
# Net Buyers: 5
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.